The Effect of Respiratory Training on Exercise Tolerance in COPD

Pulmonary Disease, Chronic Obstructive Clinical Trial

— ERTET  

Official title:

The Effect of Respiratory Training With Normocapnic Hyperpnea on Exercise Tolerance in COPD

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04201522
• Other study ID #: CER 21411
• Status: Recruiting
• Phase: N/A
• Start date: March 14, 2017
• Est. completion date: February 2021

Study information

• Verified date: December 2019
• Source: Laval University
• Contact: Ferid Oueslati, PhD
• Phone: +1 (418) 656-8711
• Email: ferid.oueslati[@]criucpq.ulaval.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Exercise intolerance is one of the key disabling factors in patients with chronic obstructive pulmonary disease (COPD). Although multifactorial, exercise intolerance involves physiological interactions between respiratory and locomotor muscles that may contribute to further reducing exercise tolerance in COPD. The respiratory muscle work during exercise is closely related to breathing and could induce respiratory muscle fatigue in patients with COPD.

Respiratory muscle training is an intervention strategy that is sometimes proposed for some patients with COPD, especially whose with inspiratory muscle weakness. It was reported that inspiratory muscle training improves inspiratory muscle endurance and strength, dyspnea and exercise tolerance. There are two types of inspiratory muscle training, inspiratory muscle training against a resistive loading and normocapnic hyperpnoea. The advantage of normocapnic hyperpnoea compared to resistive training is the possibility to simulate the exercise ventilation level while maintaining stable the partial pressure of arterial carbon dioxide and end-tidal pressure of carbon dioxide and to solicit the inspiratory and expiratory muscles together, which could increase respiratory muscle tolerance and avoid their fatigue during whole-body exercise.

Therefore, the aim of this project is to study the effect of normocapnic hyperpnoea training on exercise tolerance in patients with COPD.

We hypothesize that greater improvement in cycling exercise tolerance will be observed following 6-weeks normocapnic hyperpnoea training compared to a sham intervention in patients with COPD.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: February 2021
• Est. primary completion date: December 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• Age = 40 years;

• Chronic airflow obstruction : FEV1/FVC < 0.7, FEV1 of 30 to 80% predicted, after bronchodilation;

Exclusion Criteria:

• Inability to perform a cycling exercise;

• Diagnosed of one of more comorbidities that may limit exercise tolerance :

cardiovascular, metabolic, endocrine, gastrointestinal, renal, neurological or rheumatologically disease;

• Recent COPD exacerbation (< 3 months);

• Recent cancer;

• A daily dose of Prednisone > 10 mg;

• Hypoxemia at rest or during exercise: PaO2 < 60 mmHg or SpO2 = 88%;

• Body mass index > 30 kg/m²;

• Pregnancy;

• Skinfold at intercostal or vastus lateralis muscle > 1.5 cm.

Related Conditions & MeSH terms

• Pulmonary Disease, Chronic Obstructive

Intervention

Other:
• Normocapnic hyperpnoea intervention
Patients will perform for 6-weeks, 15 min twice daily, 5 days a week at 60% of the peak of minute ventilation, at home by means of a respiratory device (SpiroTiger, Idiag, Fehraltorf, CH).
• Sham intervention
Patients will perform for 6-weeks, 15 min twice daily, 5 days a week at rest's minute ventilation, at home by means of a respiratory device (SpiroTiger, Idiag, Fehraltorf, CH).

Locations

Country	Name	City	State
Canada	Institut universitaire de cardiologie et de pneumologie de Québec	Québec

Sponsors (3)

Lead Sponsor	Collaborator
Laval University	Oueslati, Ferid, PhD, Saey, Didier, M.D.

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in exercise tolerance (time [seconds])	Constant workrate cycling exercise time at 75% of power peak.	Baseline (week 0), 7 weeks
Secondary	Minute ventilation responses (flow [L/min])	Minute ventilation during the constant workrate cycling exercise will be determined using a portable gas analysis system.	Baseline (week 0), 7 weeks
Secondary	Change in respiratory muscle strength (pressure [cm H2O])	Maximal inspiratory and expiratory pressures will be assessed with a portable manometer before and at end the constant workrate cycling exercise.	Baseline (week 0), 7 weeks
Secondary	Change in muscle oxygenation (from baseline [%])	Deoxyhemoglobin/myoglobin concentrations measured by near-infrared spectroscopy of intercostal and vastus lateralis muscle during the constant workrate cycling exercise	Baseline (week 0), 7 weeks
Secondary	Change in cardiac output (flow [L/min])	Arterial blood pressures and cardiac output will be non-invasively measured by a finger photoplethysmography device during the constant workrate cycling exercise	Baseline (week 0), 7 weeks
Secondary	Isometric muscle strength (force [Kg])	Maximum voluntary isometric contraction with twitch tension induced by supramaximal magnetic stimulation of the femoral nerve will be realized before and 15 minutes after the constant workrate cycling exercise.	Baseline (week 0), 7 weeks